spacer
home > ebr > summer 2007 > compatibility
PUBLICATIONS
European Biopharmaceutical Review

ComPatibility

Vaibhav Sarvesh at Frost & Sullivan evaluates the pros and cons of a unified patent system throughout the EU, and suggests a way forward that might end the impasse

The European Union (EU) is an economist’s dream. It was created to synergise the strengths of the European nations and create an economic entity which can have a formidable influence on the world economy. But the very idea of creating a single economic entity poses multiple challenges that must be managed to keep it alive. It involves creating a cordial environment for business, encouraging the individual strengths of the member nations and thus proving the concept of the ‘union’ as the superior model. The most important aspect of creating the right business environment is understanding the nature of the economies of the member nations. In the case of the EU, most of the economies are capital intensive in nature, and thus the future growth of these economies will be driven by innovation. Any future plan for the EU will have to consider creating an encouraging environment for innovators.

An efficient patent system is critical to the development of an innovation-driven industry like biotechnology. The implementation of the long discussed Community Patent System or ComPat (a unitary patent system for the member nations of the EU) is a very important change that the industry is eagerly awaiting, as it competes with the US, Japan and Asian economies to retain and attract innovators. The fact that the present system of patent protection in the EU is four times more expensive than that of the US clearly takes the competitive advantage away from the EU.

Patent protection is one of the most important mechanisms that can help the biotech industry to flourish in any economy. This is especially true for the growth of small- and mediumscale enterprises (SMEs). One way to nurture an innovationbased industry is to provide a limited period of monopoly over an innovation so that the innovators find it lucrative to continue in the industry. This is why an efficient patent system is an absolute necessity to nurture the growth of SMEs, because the most valuable asset these companies own is the patents for their innovations.

EUROPEAN VERSUS US BIOTECH

The implementation of the ComPat will correct various aspects of the biotech industry in Europe. One of the major aspects it will limit is the brain drain – the movement of innovators to the US or other lucrative economic zones in order to secure patents for their innovations. At the same time it will retain and attract investment.

The US biotech industry is a well-developed market with a comparatively efficient patent system, therefore it attracts more investment from multiple sources, including venture capitalists (€2.5 billion in venture capital was raised in 2004 compared to just €1.1 billion in venture capital raised by the European biotech industry). Venture capitalists are a crucial source of investment for the development of the biotech industry and a company’s patent portfolio has great influence over investment from them. A study published by the European Association for Bioindustries stated that the European and US biotech industries both have around 2,000 companies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Vaibhav Sarvesh joined Frost & Sullivan’s research team early this year, and had previously been working as an Analyst in the European Healthcare, Pharma & Biotech team. In the past, Vaibhav has also worked for the business development division of Frost & Sullivan. His role as a Healthcare, Pharma & Biotech Analyst includes assessing and reporting on pharma & biotech markets across Europe, the Middle East and Africa. Vaibhav has a BSc, with a specialisation in Biochemistry, Genetics and Biotechnology. He has also earned a MA in Business Administration from SBS Swiss Business School, Zurich, in collaboration with Alliance Business Academy, Bangalore. His areas of specialisation are international marketing, retail management, market research, rural marketing and marketing communication.
spacer
Vaibhav Sarvesh
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo includes Sheremetyevo Airport near Moscow to its cargo flights network.

As the fastest growing brand among the global air cargo carriers with its extensive flights network, Turkish Cargo included Sheremetyevo Airport (SVO), known as being the most important airport in Russia in terms of cargo activities, to its direct cargo flight destinations network.
More info >>

White Papers

Accelerate Your Database Lock Using Clean Patient Optics

Bioclinica

Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement